At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 121 enrolled
Drug / intervention
Placebo - Controlled Period (CP) +3 moredrug
Likely dose
Ustekinumab 45 mg - CPfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis
In Brief
A Phase 3 clinical trial evaluating Placebo - Controlled Period (CP), Ustekinumab 45 mg - CP, and 2 other interventions for Psoriasis. Completed, enrolled 121 participants across 5 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of Ustekinumab in the treatment of patients with moderate to severe psoriasis in South Korea and Taiwan.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesSouth Korea, Taiwan
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2008
Enrollment StartDec 2008
Primary CompletionSep 2009
Study CompletionMar 2010
TodayJul 2026
First PostedSep 5, 2008
Enrollment StartDec 1, 2008
Primary CompletionSep 1, 2009
Study CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 17.8 years ago
Interventions
Placebo - Controlled Period (CP)drug
Placebo, Weeks 0-12
Ustekinumab 45 mg - CPdrug
Ustekinumab 45 mg, Weeks 0-12
Placebo to ustekinumab 45 mg - after CPdrug
Placebo at Weeks 0 and 4, then ustekinumab 45 mg at Week 12 and Week 16
Ustekinumab 45 mg - after CPdrug
Ustekinumab 45 mg at Weeks 0 and 4, then placebo at Week 12 and ustekinumab 45 mg at Week 16